| Authors: |
Kim DW; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, South Korea., Gadgeel S; Department of Internal Medicine, Henry Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan., Gettinger SN; Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut., Riely GJ; Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Oxnard GR; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Mekhail T; AdventHealth Cancer Institute, Orlando, Florida., Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom., Dowlati A; Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, Ohio., Heist RS; Massachusetts General Hospital Cancer Center, Boston, Massachusetts., Wozniak AJ; UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania., Singh J; Genentech, Inc., South San Francisco, California., Cha E; Genentech, Inc., South San Francisco, California., Spahn J; Genentech, Inc., South San Francisco, California., Ou SI; University of California Irvine School of Medicine, Orange, California. |
